Isotechnika Pharma Inc. (ISA.TO) Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
12/27/2012 8:44:57 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO)'s Partner Lux Biosciences Completes Enrollment in Phase 3 Uveitis Study
7/9/2012 9:09:10 AM
More...
|
Lux Biosciences Receives Complete Response Letter from FDA for Luveniq(TM)
8/4/2010 12:19:56 PM
More...
|
Lux Biosciences, Isotechnika Pharma Inc. (ISA.TO) Receive Complete Response Letter from FDA for Voclosporin; FDA Requests Additional Information and Clinical Trial; Isotechnika Shares Dive 32.56% at 1:22PM EDT
8/4/2010 7:46:15 AM
More...
|
Lux Biosciences Names Dean Mitchell President and CEO
7/1/2010 6:59:27 AM
More...
|
FDA Cancels Advisory Committee Meeting for Coclosporin; Priority Review of Lux Biosciences' NDA Continues
6/23/2010 7:28:35 AM
More...
|
Lux Biosciences' Luveniq Receives FDA Priority Review
3/30/2010 7:01:33 AM
More...
|
Lux Biosciences Receives Acceptance of Luveniq(TM) MAA Filing from European Medicines Evaluation Agency
3/2/2010 11:04:16 AM
More...
|
Lux Biosciences Files for LUVENIQ(TM) Approval in US and Europe for Noninfectious Uveitis
2/4/2010 10:44:45 AM
More...
|
Lux Biosciences to Present at Lazard Capital Markets 6th Annual Healthcare Conference
11/16/2009 9:34:46 AM
More...
|
|